Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

New treatment prevents light-induced skin damage in EPP mice

A newly developed treatment to prevent phototoxicity, or light-induced skin damage, was found effective in a mouse model of erythropoietic protoporphyria (EPP), a common form of porphyria marked by skin hypersensitivity to sunlight and some types of artificial light, a study showed. The novel oral therapy is designed to block ABCG2, a transporter…

hCG diet triggers symptoms of AIP, leading to diagnosis in woman, 34

The so-called hCG diet for weight loss, which combines a low-calorie diet with injections of the pregnancy hormone human chorionic gonadotropin (hCG), aggravated acute intermittent porphyria (AIP) in a 34-year-old woman, according to a recent case study. This diet involves receiving hCG, a naturally produced pregnancy hormone that’s approved…

CTX450 gene-editing therapy shows promise in AHP mouse model

CTX450, an investigational gene-editing therapy for acute hepatic porphyria (AHP), was able to normalize disease-associated biomarkers in a mouse model, showing its potential as a one-time intervention for the disease. CRISPR Therapeutics, the treatment’s developer, plans to launch studies to secure approval for first-in-human clinical trials, which are…

Vitamin B6 normalizes Givlaari side effect in woman with AIP

High levels of the amino acid homocysteine — a potentially harmful side effect of Givlaari (givosiran) — were successfully normalized by vitamin B6 supplementation in a woman with hard-to-treat acute intermittent porphyria (AIP), as described in a recent case report. “Our results confirmed the importance of monitoring homocysteine…

Premenstrual pain, brain swelling leads to AIP diagnosis: Case report

A woman with premenstrual pain and a brain condition called posterior reversible encephalopathy syndrome (PRES) was eventually diagnosed with acute intermittent porphyria (AIP), as described in a recent case report. “In patients with AIP and PRES, seizures are probably the most noticeable nervous system dysfunction during acute attacks,” the…

Woman’s eventual AIP diagnosis complicated by repeat seizures

A 20-year-old Chinese woman experiencing bouts of abdominal pain and seizures eventually was diagnosed with acute intermittent porphyria (AIP), the most common form of acute porphyrias, after a series of tests. Her case highlights that “it is essential to consider acute intermittent porphyria diagnosis in patients having unexplained severe…

CEP in boy with repeat nosebleeds treated by removing his spleen

Surgical removal of the spleen effectively eased the signs and symptoms of severe congenital erythropoietic porphyria (CEP) in a 10-year-old boy with recurrent nose bleeds, according to a recent case report. “Our patient’s repeated [nose bleeds] is a rare and unreported clinical manifestation of this illness,” the scientists wrote.

Disc Medicine’s new US patent covers bitopertin therapy for EPPs

Disc Medicine has been granted a U.S. patent for treating erythropoietic protoporphyrias (EPPs) with glycine transport inhibitors, such as its investigational oral therapy bitopertin. “We are pleased to have been issued this patent that further secures [intellectual property] protection for bitopertin for the treatment of erythropoietic protoporphyria as…